News

Millie Hughes-Fulford, PhD, a UC San Francisco scientist who flew in June 1991 aboard the first space shuttle mission dedicated to biomedical studies, died Feb. 2 at the age of 75. She was the first woman to fly as a NASA payload specialist and was part of the first crew to include three women. On

For all their importance as a breakthrough treatment, the cancer immunotherapies known as checkpoint inhibitors still only benefit a small minority of patients, perhaps 15 percent across different types of cancer. Moreover, doctors cannot accurately predict which of their patients will respond. A

In September, the North Complex West Zone fire ripped through Butte County, killing 16 residents and decimating more than 2,000 structures. The structures destroyed in the blaze included almost all of the cabins, bathrooms and main buildings that make up Okizu – a 500-acre refuge for families of

Matthew Bucknor, MD's interest in focused ultrasound developed during his radiology residency at UCSF when Fergus Coakley, MD (former faculty and current chair of radiology at Oregon Health Sciences University) brought the technology here. At that time, Dr. Bucknor was unsure if he wanted to pursue

Scientists at UC San Francisco’s Quantitative Bioscience Institute (QBI) and the Icahn School of Medicine at Mt. Sinai (ISMMS) in New York have shown that plitidepsin (Aplidin), a drug approved by the Australian Regulatory Agency for the treatment of multiple myeloma, has potent antiviral activity

Over the past 15 years, the cancer center’s Community Advisory Board (CAB) has become one of UCSF’s most instrumental community outreach groups for improving health equity. In a Q&A below, CAB Chair Arnold Perkins and Dr. Kim Rhoads discuss why CABs are critical to the work of NCI cancer centers and

UC San Francisco scientists have discovered a new way to control the immune system’s “natural killer” (NK) cells, a finding with implications for novel cell therapies and tissue implants that can evade immune rejection. The findings could also be used to enhance the ability of cancer immunotherapies